Prasugrel Benefits Patients With Diabetes and Multivessel Disease Post-PCI: TUXEDO-2 Trial

The findings from the TUXEDO‑2 trial provide important clinical insights for managing high‑risk patients with diabetes and multivessel coronary disease undergoing stenting. By directly comparing ticagrelor and prasugrel within a dual antiplatelet therapy regimen, the trial helps clarify whether one agent offers superior protection in this complex population. These results may influence clinical decision‑making, particularly if meaningful differences in outcomes are demonstrated.

In this interview, Sidney C. Smith Jr., MD, MACC and Sripal Bangalore, MD, MHA discuss the TUXEDO-2 Trial.